Compare Gilead Sciences, Inc. (GILD) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.95 (market cap $168.35B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.78. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | QDTY | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $46.71 |
52-Week Low | $110.56 | $36.57 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
QDTY trades at $39.75, showing minimal daily movement with a -0.13% decline. The technical picture remains neutral overall with bearish moving averages, while the company demonstrates consistent dividend distributions through its weekly payout structure. Recent YieldMax ETF announcements highlight ongoing distribution activities through mid-2026.
The stock presents income-focused appeal through regular distributions, though fundamental metrics remain unavailable for comprehensive valuation assessment. Key considerations include reliance on ETF distribution strategies and market volatility exposure. The neutral technical stance suggests limited near-term directional momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
